Tagged with Big Pharma

Global During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing power structure of the industry and the factors driving the evolution of the pharma innovation model. The session was moderated by Deloitte global life sciences and health care leader…

Novartis In the latest in a wave of Big Pharma companies retreating from the field of antibiotics, Novartis has decided to drop its antibacterial and antiviral early-stage research programs, laying off 140 staff in the US. This comes at a time when antibiotic-resistant strains of bacteria – so-called ‘superbugs’ – are…

India For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India country president Jawed Zia points out that “India, in terms of demographics, is the youngest nation in the world. The…

Lithuania Rūta Pumputienė, head of the Local American Working Group (LAWG), explains the main dynamics impacting the pharmaceutical sector in general as well as the key role of the LAWG in supporting the better access to innovative treatments. Can you please introduce yourself to our international audience as well as the…

Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…

Canada Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed and modernized pharmaceutical framework agreement between industry and government, and the strong business case Canada needs to make in order…

Indonesia Milan Paleja, country president and general manager of Novartis Indonesia, discusses his main priorities since assuming his current position and the organization’s business expansion strategy, based on enhancing patient access to innovative medicines in both the public and private sectors. Mr. Paleja, you were appointed as country president and general…

Hong Kong Andy Barnett, general manager (Hong Kong and Macau) for Roche, discusses the highlights of his past two years managing a local affiliate instead of heading a global business line, the key factors behind Roche’s top-5 positioning in the local market, and the huge potential for innovation in aspects like digital…

Colombia Pfizer’s country manager and PEH Lead for Colombia & Venezuela, Diego Forero, shares his insights on the Colombian pharmaceutical market, his goals for Pfizer’s Colombian affiliate, and how Colombian operations fit into the group’s worldwide strategy. You just returned after eight years in the USA to lead Pfizer’s Colombian affiliate.…

Indonesia Omar Luqmaan Harris, GM at GSK Indonesia, discusses the commitment of the Indonesian affiliate to the global organization’s mission, as well as their focus on being the best place to work, with the highest patient focus, and the best customer engagement. Mr. Harris, what have been your main areas of…

Colombia Spearheading the Colombian affiliate of the global leader in oncology, Carlos Estrada, General Manager of Roche Colombia shares his insights on the profound transformations of the Colombian healthcare system. He speaks about achieving optimal equilibrium in the system, the exciting pipeline ahead for Roche, as well as their strategies to…

Ireland Chairman for BioPharmaChemical Ireland and Leader of Pfizer’s two small molecule API manufacturing sites in Cork, Seamus Fives recounts his team’s efforts to avert the closure of the Little Island facility through improvements in operating efficiency, and discusses how Pfizer is re-equipping their small molecule facilities to fit the needs…